par Metzger-Filho, Otto;Saini, Kamal
;Abdel Azim, Hatem Hamdy
;Awada, Ahmad
;Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME),
Référence Critical reviews in oncology/hematology, 84 Suppl 1, page (e79-e85)
Publication Publié, 2012-12



Référence Critical reviews in oncology/hematology, 84 Suppl 1, page (e79-e85)
Publication Publié, 2012-12
Article révisé par les pairs
Titre: |
|
Auteur: | Metzger-Filho, Otto; Saini, Kamal; Abdel Azim, Hatem Hamdy; Awada, Ahmad; Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME), |
Informations sur la publication: | Critical reviews in oncology/hematology, 84 Suppl 1, page (e79-e85) |
Statut de publication: | Publié, 2012-12 |
Sujet CREF: | Cancérologie |
Mots-clés: | Bevacizumab |
Lapatinib | |
Management incidence | |
Prevention | |
Targeted therapy | |
Toxicity | |
Trastuzumab | |
MeSH keywords: | Animals |
Antibodies, Monoclonal, Humanized -- adverse effects | |
Antineoplastic Agents -- adverse effects | |
Breast -- drug effects | |
Breast Neoplasms -- drug therapy | |
Cardiovascular Diseases -- chemically induced -- prevention & control | |
Female | |
Gastrointestinal Diseases -- chemically induced -- prevention & control | |
Humans | |
Molecular Targeted Therapy -- methods | |
Quinazolines -- adverse effects | |
Skin Diseases -- chemically induced -- prevention & control | |
Note générale: | Journal Article |
Review | |
SCOPUS: re.j | |
Langue: | Anglais |
Identificateurs: | urn:issn:1040-8428 |
info:doi/10.1016/j.critrevonc.2010.07.014 | |
info:pii/S1040-8428(10)00181-2 | |
info:scp/84871681602 | |
info:pmid/20817545 |